Erasca Expands Joyo Pharmatech License To China, Hong Kong, And Macau, Securing Worldwide Rights To pan-RAS Molecular Glue ERAS-0015

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy

ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent

Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will provide Erasca with worldwide rights to its potential best-in-class pan-RAS molecular glue ERAS-0015.

Under the terms of the ERAS-0015 license agreement, Erasca exercised its option to convert its territory to worldwide and is obligated to make a one-time payment to Joyo based on the stage of Joyo's development program. Securing rights in China, Hong Kong, and Macau will provide Erasca with exclusive global rights for ERAS-0015, enabling the company to pursue a unified worldwide development and commercialization strategy.